The Infant Development, Environment, and Lifestyle Study: Effects of Prenatal Methamphetamine Exposure, Polydrug Exposure, and Poverty on Intrauterine Growth

Smith, Lynne M.; LaGasse, Linda L.; Derauf, Chris; Grant, Penny; Shah, Rizwan; Arria, Amelia M.; Huestis, Marilyn A.; Haning, William; Strauss, Arthur; Grotta, Sheri Della; Liu, Jing; Lester, Barry M.

doi:10.1542/peds.2005-2564

Cited by 253 publications

(168 citation statements)

References 38 publications

Supporting

Mentioning

157

Contrasting

Unclassified

Order By: Relevance

“…MA is a powerful psychostimulant that upon administration blocks monoamine transporters for dopamine, serotonin, and norepinephrine and causes release of these neurotransmitters into the synaptic cleft, therefore resulting in a sustained presence of these neurotransmitters in the cleft (Kucaenski and Segal, 1994). While the literature on prenatal MA exposure is limited, there is an association between MA and low birth weight and length, decreased head circumference, and increased fetal distress (Chomchai et al, 2004;Little et al, 1988;Smith et al, 2006). Reductions in the volume of the caudate, putamen, globus pallidus, and hippocampus were observed in children who were prenatally exposed to MA (Chang et al, 2004).…”

Section: Introductionmentioning

confidence: 99%

Neonatal (+)-methamphetamine increases brain derived neurotrophic factor, but not nerve growth factor, during treatment and results in long-term spatial learning deficits

Skelton

Williams

Schaefer

2007

Psychoneuroendocrinology

View full text Add to dashboard Cite

SummaryIn this study, brain derived neurotrophic factor (BDNF) and nerve growth factor (NGF) were examined at five time points [postnatal day (P)11, 15, 20, 21, and 68 (the latter with or without behavioral testing)] during and after P11-20 (+)-methamphetamine (MA) (10 mg/ kg 4 × day) treatment. BDNF in MA-treated animals was elevated on P15 and P20 in the hippocampus but not in the hypothalamus and was unchanged on P11 and P21. On P68 (1 h after Morris water maze testing) MA-treated offspring showed a trend toward higher levels of BDNF in the hippocampus than saline-treated animals. MA treatment increased NGF levels in the hippocampus but only on P20. No effect of MA treatment was observed in the elevated zero maze. MA-treated offspring had increased latencies, cumulative distances, path lengths, and first bearings in the Morris water maze. The findings indicate that early MA exposure induces hippocampal BDNF increases that precede the later emergence of spatial learning deficits.

show abstract

Section: Introductionmentioning

confidence: 99%

Neonatal (+)-methamphetamine increases brain derived neurotrophic factor, but not nerve growth factor, during treatment and results in long-term spatial learning deficits

Skelton

Williams

Schaefer

2007

Psychoneuroendocrinology

View full text Add to dashboard Cite

show abstract

“…Detailed recruitment methods for the IDEAL study have been reported previously. 4,27 This study was approved by the institutional review boards at each site, and written informed consent was obtained from all subjects. A National Institute on Drug Abuse Certificate of Confidentiality was obtained that assured confidentiality of information regarding the mothers' drug use.…”

Section: Methodsmentioning

confidence: 99%

Prenatal Methamphetamine Exposure and Childhood Behavior Problems at 3 and 5 Years of Age

2012

PEDIATRICS

View full text Add to dashboard Cite

WHAT'S KNOWN ON THIS SUBJECT: Prenatal methamphetamine exposure has been related to deficits in fetal growth, changes in infant neurobehavior, and fine motor deficits, but little is known about its developmental effects on behavior problems in early childhood. WHAT THIS STUDY ADDS:This is the first prospective study to identify behavior problems associated with prenatal methamphetamine exposure. Mood difficulties and acting-out behavior are increased in exposed children by age 3 years. Early identification and intervention may prevent escalation into delinquency and psychopathology. abstract OBJECTIVE: We evaluated behavior problems in children who were prenatally exposed to methamphetamine (MA) at ages 3 and 5 years. METHODS:The Infant Development, Environment, and Lifestyle study, a prospective, longitudinal study of prenatal MA exposure and child outcome, enrolled subjects postpartum in Los Angeles, California; Honolulu, Hawaii; Des Moines, Iowa; and Tulsa, Oklahoma. Prenatal exposure was determined by maternal self-report and/or meconium results. Exposed and comparison groups were matched on race, birth weight, public health insurance, and education. Mothers in the comparison group denied use and had a negative meconium screen for amphetamines. Prenatal exposures to tobacco, alcohol, or marijuana occurred in both groups. At ages 3 and 5 years, 330 children (166 exposed and 164 comparison) were assessed for behavior problems by using the caregiver report on the Child Behavior Checklist. General linear mixed models were used to determine the effects of prenatal MA exposure, including heavy exposure ($3 days per week), age, and the interaction of exposure and age on behavior problems with adjustment for other drugs of abuse and environmental risk factors. RESULTS:MA exposure was associated with increased emotional reactivity and anxious/depressed problems at both ages and externalizing and attention-deficit/hyperactivity disorder problems by age 5 years. Heavy exposure was related to attention problems and withdrawn behavior at both ages. There were no effects of MA on the internalizing or total behavior problems scales.CONCLUSIONS: This first report of behavior problems in patients as young as 3 years associated with MA exposure identifies an important public health problem. Continued follow-up can inform the development of preventive intervention programs. Pediatrics 2012;129:681-688

show abstract

“…1 Now at Curtin University of Technology, Perth, WA, Australia utero methamphetamine (MAMP) or amphetamine (AMP) exposure, either alone or in combination with other drugs such as cocaine. [3][4][5][6][7] Human neonatal outcomes after in utero exposure to methylenedioxy-derivatives of AMP, such as 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) are not well understood. Exposed infants may be identified by maternal self-report or chromatographic confirmation of MAMP, AMP, MDMA and/or metabolites in meconium.…”

Section: Introductionmentioning

confidence: 99%

Development and validation of a liquid chromatography–atmospheric pressure chemical ionization-tandem mass spectrometry method for simultaneous analysis of 10 amphetamine-, methamphetamine- and 3,4-methylenedioxymethamphetamine-related (MDMA) analytes in human meconium

Kelly

Gray

Huestis

2008

Journal of Chromatography B

View full text Add to dashboard Cite

A liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry (LC-APCI-MS/MS) method for quantification of ten amphetamine-related analytes in 1 g meconium is presented. Specimen preparation included homogenization and solid phase extraction. Two multiple reaction monitoring transitions were monitored per analyte. Ten and 1 µL injection volumes permitted quantification up to 10,000 ng/g, with sufficient sensitivity to quantify minor metabolites. Lower limits of quantification ranged from 1.25 to 40 ng/g. Precision was less than 14.2%, with accuracy between 79 -115%. Meconium from a methamphetamine-exposed neonate was analyzed. Metabolites p-hydroxymethamphetamine, norephedrine and 4-hydroxy-3-methoxymethamphetamine were identified in meconium for the first time.

show abstract

The Infant Development, Environment, and Lifestyle Study: Effects of Prenatal Methamphetamine Exposure, Polydrug Exposure, and Poverty on Intrauterine Growth

Abstract: These findings suggest that prenatal methamphetamine use is associated with fetal growth restriction after adjusting for covariates. Continued follow-up will determine if these infants are at increased risk for growth abnormalities in the future.

Cited by 253 publications

References 38 publications

Neonatal (+)-methamphetamine increases brain derived neurotrophic factor, but not nerve growth factor, during treatment and results in long-term spatial learning deficits

Neonatal (+)-methamphetamine increases brain derived neurotrophic factor, but not nerve growth factor, during treatment and results in long-term spatial learning deficits

Prenatal Methamphetamine Exposure and Childhood Behavior Problems at 3 and 5 Years of Age

Development and validation of a liquid chromatography–atmospheric pressure chemical ionization-tandem mass spectrometry method for simultaneous analysis of 10 amphetamine-, methamphetamine- and 3,4-methylenedioxymethamphetamine-related (MDMA) analytes in human meconium

Contact Info

Product

Resources

About